Date: 2017-01-05
Type of information: Restructuring
Compound:
Company: Eli Lilly (USA - IN)
Therapeutic area:
Type agreement: restructuring
Action mechanism:
Disease:
Details:
- • On January 5, 2017, Eli Lilly announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. These organizational changes are expected to increase productivity and simplify Lilly's global commercial organization. These changes will also result in a reduction in leadership positions. In December, the company announced reductions to its U.S. field force in anticipation of patent expirations for key products later this year and in response to clinical trial results on solanezumab.
- Christi Shaw has been hired to lead the company's Bio-Medicines business beginning April 3. Shaw will succeed Ricks, who became Lilly's president and CEO on January 1, as senior vice president and president of Lilly Bio-Medicines. In her new role, Shaw will lead important areas of potential growth for Lilly—immunology, neurodegeneration, and pain, as well as many of the company's established brand products. Shaw, who started her career at Lilly in 1989, has more than 25 years of pharmaceutical and medical device experience.
Beginning on February 1, Lilly's Diabetes, Oncology and Bio-Medicines human pharmaceutical therapeutic business areas will assume commercial responsibility for their products in China—in addition to the U.S., Japanese and Canadian markets in which they already operate.
- Lilly Diabetes will host the company's human pharmaceutical commercial operations in the United States, China, Japan and Canada. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes, will assume additional responsibilities as president of Lilly USA.
Lilly's current Emerging Markets business will combine with Europe to form Lilly International, which will have commercial responsibility for the company's human pharmaceutical products in these markets. Alfonso Zulueta, who has led the Emerging Markets business for the last three years, will be senior vice president of Lilly and president of Lilly International.
Sue Mahony, Ph.D., will continue as senior vice president of Lilly and president of Lilly Oncology.
Alex Azar, president of Lilly USA, has decided to leave Lilly to pursue other career opportunities.
Financial terms:
Latest news:
Is general: Yes
